Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.59 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.59 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.59 |
| ▸ | FAP | Q12884 | 1/20 | 0.59 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | GLMN | Q92990 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4594530 | 1.00 | DPP4 (0.59) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL12354533 | 0.85 | DPP4 (0.60) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL1038132 | 0.76 | DPP4 (0.73) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL30730737 | 0.76 | DPP4 (0.73) | DPP4DPP8DPP9FAPDPP7 | |
| Vildagliptin SCHEMBL16823370 | 0.74 | DPP4 (1.00) | DPP4DPP8DPP9FAP | |
| Vildagliptin SCHEMBL665401 | 0.74 | DPP4 (1.00) | DPP4DPP8DPP9FAP | |
| Vildagliptin SCHEMBL671629 | 0.74 | DPP4 (1.00) | DPP4DPP8DPP9FAP | |
| Vildagliptin SCHEMBL16579 | 0.74 | DPP4 (1.00) | DPP4DPP8DPP9FAP | |
| Vildagliptin SCHEMBL10031674 | 0.74 | DPP4 (1.00) | DPP4DPP8DPP9FAP | |
| Vildagliptin SCHEMBL665400 | 0.74 | DPP4 (1.00) | DPP4DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253752-A1 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFIN | BURKEY BRYAN | 2009-10-08 | — | — | US | disclosed |
| US-20080299190-A1 | Direct Compression Formulation and Process | NOVARTIS AG (CH) | 2008-12-04 | — | — | US | disclosed |
| US-20080221200-A1 | Combination of Organic Compounds | ALLISON MALCOLM | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080299190-A1 | Direct Compression Formulation and Process | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 6/4885DPP9 4/4885 |
| US-20090253752-A1 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFIN | PPARG, DPP4, DPP3 | DPP4 2/4885DPP8 7/4885DPP9 10/4885 |
| US-20080221200-A1 | Combination of Organic Compounds | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.